--- title: "ProImmune 推出 “掌握免疫力 2026”——上海研討會，旨在解決關鍵的免疫原性挑戰" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/273211867.md" description: "ProImmune Ltd 宣佈將於 2026 年 4 月 13-14 日在上海東方濱江酒店舉辦 “掌握免疫力 2026” 研討會。此次首屆活動將聚焦於藥物開發中的免疫原性挑戰，邀請全球生物治療領域的領導者和監管機構的專家參與。研討會旨在提供管理免疫原性風險的實用指導，這些風險可能對藥物項目的成功產生重大影響。知名演講者包括來自 FDA、輝瑞和羅氏的專家。該活動被視為中國生物製藥行業從業者的必 attend 會議" datetime: "2026-01-21T10:05:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273211867.md) - [en](https://longbridge.com/en/news/273211867.md) - [zh-HK](https://longbridge.com/zh-HK/news/273211867.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273211867.md) | [English](https://longbridge.com/en/news/273211867.md) # ProImmune 推出 “掌握免疫力 2026”——上海研討會，旨在解決關鍵的免疫原性挑戰 **ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges** - _Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape_ - _Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities_ - _In-person event taking place at Oriental Riverside Hotel, Shanghai, 13-14 April 2026_ ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 – Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk. Taking place at the Oriental Riverside Hotel in Shanghai, the event will convene leading scientists, industry executives, and regulatory professionals from around the world. Immunogenicity, the potential for biologics to trigger unwanted immune responses, remains a decisive factor in determining safety, efficacy, and regulatory and commercial success. When immunogenicity is poorly understood or assessed inadequately, development programs face clinical failure, costly redesigns, and significant delays. In some cases, these risks can lead to the loss of entire programs, representing financial impacts in the hundreds of millions or even billions of dollars, as well as extended timelines required for additional studies or reformulation. Presentations will cover modality-specific insights based on real world examples for emerging therapeutic platforms and perspectives on evolving global regulatory expectations presented by speakers from leading companies and regulators with experience of bringing successful drugs to market, including: - Dr. Zuben Sauna (Director, Center for Biologics Evaluation and Research, FDA) - Dr. Sophie Tourdot (Immunogenicity Sciences Lead, Pfizer) - Dr. Balaji MR (Vice President and Head – Non Clinical, Dr. Reddy’s Laboratories) - Dr. Daniela Verthelyi (Former Chief, Laboratory of Immunology, Office of Biotechnology Products, FDA) - Dr. Tim Hickling (Former Head of Immunosafety, Roche, Quasor) - Dr. Kanthikiran Varanasi (Global Head of Clinical Affairs, Galencium) - Andreas Hollenstein (Senior Principal Scientist, Immunosafety, Roche) - Dr. Nitinkumar Dobaria (Associate Director, Injectables Product Development, Lupin) - Dr. Anuj Saini (Global Head-Global Clinical Management, Dr Reddy’s Laboratories) - Prof. Yoonjoo Choi (Professor, Department of Microbiology and Immunology, Chonnam National University Medical School) **Dr. Juhao Yang, Toxicology Project Leader, China Innovation Center of Roche shared:** _"This meeting is a pivotal moment, bringing together global leaders to tackle the urgent challenge of immunogenicity risk and drive better patient outcomes. This is a must-attend event for anyone committed to shaping the future of biotherapeutics.”_ **Dr. Nikolai Schwabe, Chief Executive Officer, ProImmune, added:** “_Licensing activity and clinical trials are at an all-time high in China’s biopharmaceutical industry, but the regulatory landscape is still evolving. By connecting immunogenicity leaders from around the world to share experiences including development and regulatory best practice, ProImmune is playing a critical role in helping developers manage the risk around immunological effects and ultimately accelerate the development of successful therapeutic products.__”_ For event details and registration, including early-bird, visit: https://www.proimmune.com/mastering-immunity-2026-shanghai **Media Contact** Francesca Wallace Zyme Communications Email: francesca.wallace@zymecommunications.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260121510655/en/ ### 相關股票 - [羅氏(ADR) (RHHBY.US)](https://longbridge.com/zh-HK/quote/RHHBY.US.md) - [標普全球醫療股指數 ETF - iShares (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [生物科技 ETF - VanEck Vectors (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [標普生物技術 ETF - SPDR (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [美國制藥 ETF - iShares (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [醫療業 ETF - SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [納斯達克生物科技指數 ETF - iShares Nasdaq (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [輝瑞 (PFE.US)](https://longbridge.com/zh-HK/quote/PFE.US.md) - [醫藥突破 ETF - ALPS (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [2 倍做多納斯達克生物技術 ETF - ProShares (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [動態生物技術與基因組 ETF - Invesco (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [基因改革 ETF - ARK (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [紐交所高增長板生物技術指數 ETF - First Trust (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Immuneering (IMRX.US)](https://longbridge.com/zh-HK/quote/IMRX.US.md) - [醫療業 ETF - Vanguard (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) ## 相關資訊與研究 - [和黃醫藥在中、美啟動第二款抗體靶向偶聯藥物 1 或 2A 期臨牀試驗](https://longbridge.com/zh-HK/news/277750256.md) - [重塑全球免疫治療版圖！生華科與耶魯 AI 新創 CellType 簽署重大合作](https://longbridge.com/zh-HK/news/277603424.md) - [奧孟亞積極進軍國際口服 GLP-1 市場 ANY004 澳洲臨牀一期試驗啟動](https://longbridge.com/zh-HK/news/277746247.md) - [鉅亨速報 - Factset 最新調查：BeOne Medicines Ltd. Sponsored ADR(ONC-US) EPS 預估下修至 5.83 元，預估目標價為 411.00 元](https://longbridge.com/zh-HK/news/277664352.md) - [鉅亨速報 - Factset 最新調查：ImmunityBio Inc(IBRX-US) EPS 預估上修至-0.26 元，預估目標價為 12.00 元](https://longbridge.com/zh-HK/news/277809469.md)